FY2017 EPS Estimates for Intersect ENT Inc Decreased by Leerink Swann (XENT)
Intersect ENT Inc (NASDAQ:XENT) – Equities researchers at Leerink Swann dropped their FY2017 earnings estimates for Intersect ENT in a note issued to investors on Tuesday. Leerink Swann analyst R. Newitter now anticipates that the medical equipment provider will post earnings of ($0.71) per share for the year, down from their previous forecast of ($0.70). Leerink Swann also issued estimates for Intersect ENT’s FY2018 earnings at ($0.44) EPS and FY2019 earnings at $0.03 EPS.
Other equities analysts have also issued reports about the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $16.00 target price on shares of Intersect ENT in a research note on Tuesday, February 21st. Northland Securities reaffirmed a “buy” rating and issued a $17.00 target price on shares of Intersect ENT in a research note on Monday, March 13th. Deutsche Bank AG raised shares of Intersect ENT from a “hold” rating to a “buy” rating and upped their target price for the stock from $15.00 to $19.00 in a research note on Monday, March 6th. Zacks Investment Research raised shares of Intersect ENT from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 3rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Intersect ENT in a research note on Wednesday, May 10th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Intersect ENT has a consensus rating of “Buy” and an average target price of $18.60.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/05/25/fy2017-eps-estimates-for-intersect-ent-inc-decreased-by-leerink-swann-xent.html.
Shares of Intersect ENT (NASDAQ:XENT) opened at 23.75 on Thursday. The stock’s market capitalization is $683.34 million. Intersect ENT has a one year low of $7.65 and a one year high of $25.10. The company’s 50 day moving average price is $20.17 and its 200 day moving average price is $14.89.
Intersect ENT (NASDAQ:XENT) last issued its earnings results on Tuesday, May 2nd. The medical equipment provider reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The business had revenue of $20.47 million during the quarter, compared to analysts’ expectations of $19.39 million. Intersect ENT had a negative return on equity of 21.25% and a negative net margin of 35.69%.
Several institutional investors have recently bought and sold shares of XENT. Adage Capital Partners GP L.L.C. increased its position in Intersect ENT by 129.4% in the third quarter. Adage Capital Partners GP L.L.C. now owns 400,000 shares of the medical equipment provider’s stock worth $6,336,000 after buying an additional 225,649 shares in the last quarter. Moors & Cabot Inc. increased its position in Intersect ENT by 0.9% in the third quarter. Moors & Cabot Inc. now owns 10,950 shares of the medical equipment provider’s stock worth $175,000 after buying an additional 100 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Intersect ENT during the fourth quarter worth approximately $377,000. State Street Corp increased its position in Intersect ENT by 12.8% in the fourth quarter. State Street Corp now owns 459,327 shares of the medical equipment provider’s stock worth $5,550,000 after buying an additional 51,973 shares in the last quarter. Finally, FMR LLC acquired a new position in Intersect ENT during the fourth quarter worth approximately $1,452,000. Institutional investors own 77.81% of the company’s stock.
In other news, insider Lisa D. Earnhardt sold 20,000 shares of the stock in a transaction dated Monday, April 17th. The shares were sold at an average price of $16.06, for a total transaction of $321,200.00. Following the completion of the transaction, the insider now directly owns 610,868 shares in the company, valued at approximately $9,810,540.08. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last 90 days, insiders have sold 81,250 shares of company stock valued at $1,560,163. Company insiders own 13.90% of the company’s stock.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc and related companies with MarketBeat.com's FREE daily email newsletter.